Placebo for AIDSVAX B/E

BIOLOGICAL2 trials

Sponsors

HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionHIV Infections

Phase 1

Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults

CompletedNCT02109354

HIV Vaccine Trials NetworkHIV Infection

Start: 2013-06-18End: 2015-02-02Updated: 2019-06-21

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

CompletedNCT02207920

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2014-07-31End: 2015-12-31Updated: 2021-10-15

Related Papers

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Emerging Microbes & Infections2025-04-071 citations

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations

Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans

AIDS Research and Human Retroviruses2023-02-104 citations

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

PLoS Pathogens2021-11-292 citations

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.

2020-01-3016 citations

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

Journal of Clinical Investigation2019-09-3035 citations

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa

PLoS ONE2014-11-179 citations